Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Infections and Infectious Diseases Phase II
Italy 
Details:
Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The REPAVID-19 clinical trial will evaluate efficacy and safety of Dompé’s Reparixin in hospitalized adult patients with severe COVID-19 pneumonia.
Lead Product(s): Reparixin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
This new funding from BARDA will enable Sabin and ReiThera to advance the investigational Ebola Sudan and Marburg vaccines through GMP manufacturing and release of ChAd3-MARV and ChAd3-SUDV Phase 2 clinical trial.
Lead Product(s): ChAd3-SUDV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $215.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2020
